Novocure Ltd (NVCR)

[dstock07734]

In 2016, NCI sponsored a massive clinical trial on rare cancers. Take a look at the list of all rare cancers. The missing one was GBM. Was it because Optune was a huge success back then? I guess not. It was because the combo trial of DCVax-L and poly-iclc was completed in January 2015. NCI found that there was no need to include GBM in the list.

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
https://classic.clinicaltrials.gov/ct2/show/NCT02834013?cond=rare+cancer&lead=National+cancer+institute&draw=2&rank=10

https://classic.clinicaltrials.gov/ct2/show/NCT01204684?cond=glioblastoma&spons=Jonsson&draw=2&rank=15